1
|
Albitar A, Ma W, DeDios I, Estella J, Agersborg S, Albitar M. Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acid. Int J Lab Hematol 2016; 38:133-40. [PMID: 26797804 DOI: 10.1111/ijlh.12456] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Accepted: 11/12/2015] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Detection of mutations in the myeloid differentiation primary response gene 88 (MYD88) has clinical implications on diagnosis and therapy, especially in patients with Waldenström's macroglobulinemia (WM) and IgM monoclonal gammopathy of unknown significance (IgM-MGUS). We describe a method that provides greatly increased sensitivity for detecting minority mutations in MYD88. METHODS We used a locked nucleic acid oligonucleotide to block amplification of wild-type DNA during polymerase chain reaction (PCR). Sanger sequencing of amplified DNA was used for detecting mutations in MYD88 gene. This approach was used to test samples from patients with WM and IgM-MGUS. RESULTS When compared to traditional PCR followed by Sanger sequencing, our methodology was significantly more sensitive (one mutant allele in a background of 200 wild-type alleles). Using sequencing allowed us to visualize the PCR product, giving advantages over other methodologies such as allele-specific PCR. Based on analyzing 36 randomly selected, MYD88 mutated, clinically tested samples, we demonstrate that traditional PCR failed to detect MYD88 mutations in 64% of the samples that were clearly positive by wild-type blocking PCR. CONCLUSION The new methodology is essential for attaining accurate results in clinical testing.
Collapse
Affiliation(s)
- A Albitar
- NeoGenomics Laboratories, Irvine, CA, USA
| | - W Ma
- NeoGenomics Laboratories, Irvine, CA, USA
| | - I DeDios
- NeoGenomics Laboratories, Irvine, CA, USA
| | - J Estella
- NeoGenomics Laboratories, Irvine, CA, USA
| | | | - M Albitar
- NeoGenomics Laboratories, Irvine, CA, USA
| |
Collapse
|
2
|
Abstract
MDM-2 is an oncoprotein that seems to function, at least in part, by interacting with the p53 protein and modulating its tumor-suppressing activity. The MDM-2 gene codes for p57, p74, p76, p85, and p90 proteins. Overexpression of only the p90 MDM-2 protein has been reported in sarcomas showing MDM-2 gene amplification. In addition, post-transcriptional mechanisms have been demonstrated to play a role in the expression of MDM-2 proteins. We investigated MDM-2 gene amplification, mRNA and protein levels in various cases of sarcomas. We found MDM-2 gene amplification in 12 (26%) of 46 cases of sarcoma: 11 of 13 cases of liposarcoma and 1 of 6 cases of malignant fibrous histiocytoma. The MDM-2 amplification correlated with the presence of elevated levels of mRNA and protein in the liposarcomas. In sarcomas other than liposarcomas, mRNA was overexpressed in 7 (30%) of 23 cases, without MDM-2 amplification. In 15 (62.5%) of 24 cases of sarcoma and in 1 case of lipoma the MDM-2 protein was overexpressed as shown by Western blot analysis. Interestingly, p57 not p90 was the most commonly overexpressed MDM-2 protein. These data indicate that the molecular abnormalities affecting MDM-2 expression in cases of sarcoma include transcriptional, post-transcriptional, and gene dosage (amplification) mechanisms. Furthermore, our findings suggest that MDM-2 p57 protein may be as important as p90 in the pathogenesis of human sarcomas.
Collapse
Affiliation(s)
- C Buesoramos
- UNIV TEXAS,MD ANDERSON CANCER CTR,DIV LAB MED,HEMATOPATHOL PROGRAM,HOUSTON,TX 77030. UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PATHOL,HOUSTON,TX 77030
| | | | | | | | | | | | | |
Collapse
|
3
|
Landgren O, Ma W, Kyle RA, Rajkumar SV, Korde N, Albitar M. Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma. Leukemia 2011; 26:844-5. [PMID: 21926963 DOI: 10.1038/leu.2011.262] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
4
|
Ma W, Giles F, Zhang X, Wang X, Zhang Z, Lee TS, Yeh CH, Albitar M. Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors. Int J Lab Hematol 2011; 33:326-31. [PMID: 21266020 DOI: 10.1111/j.1751-553x.2010.01291.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
INTRODUCTION Multiple types of mutations in the BCR-ABL1 kinase domain have been reported. We previously reported a common alternatively spliced BCR-ABL mRNA with a 35-nucleotide insertion (35INS). We report three novel alternative splicing mutants expressed as the dominant transcripts in patient with chronic myelogenous leukemia and resistance to kinase inhibitors. METHODS We screened RNA from more than 200 patients with resistance to more than one of the three kinase inhibitors for ABL1 kinase domain mutations by direct sequencing. RESULTS We found three not previously described splice mutants. All three showed >90% mutant transcript. The first resulted from the insertion of 79 nucleotides into the ABL1 exon 8-9 junction. The inserted sequence contained a sequence from regions of intron 8, located 120 bp apart: the 35-nucleotide sequence previously described, and an additional 44-nucleotide segment downstream from 35INS. The combined 79-nucleotide insertion splice mutant showed the same protein change as 35INS (p C475YfsX11). The second splice mutation comprised an 84-nucleotide sequence from intron 7 inserted into the ABL1 exon7-8 junction, also causing a frameshift and protein truncation (p A424EfsX18). The third splice derived from a 231-nucleotide sequence from intron 4 retained in the ABL1 exon 4-5 junction adding 40 intron-encoded amino acids and leading to a frameshift and early termination (p E275LfsX41). CONCLUSION These findings, when combined with the data on 35INS, support the concept that loss of the C-terminus of BCR-ABL1 is associated with significant resistance to kinase inhibitors; this mechanism appears to be a major source of resistance to kinase inhibitors.
Collapse
Affiliation(s)
- W Ma
- Department of Hematology/Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Ma W, Kantarjian H, Zhang X, Yeh CH, Zhang ZJ, Verstovsek S, O'Brien S, Giles F, Albitar M. Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology. Int J Lab Hematol 2010; 32:95-102. [PMID: 19254349 DOI: 10.1111/j.1751-553x.2009.01140.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The association of V617F JAK2 expression levels with disease behavior has not been studied in patients with nonchronic myelogenous leukemia (CML) myeloproliferative disease (MPD). We found plasma levels of total JAK2 mRNA to be higher in patients with non-CML MPD (n=175) than in CML patients (n=45) and normal controls (n=58) (each P<0.001). Overall survival was studied in 68 patients and showed positive correlation with levels of total and mutant JAK2 mRNA in patients with the V617F mutation, but not those without the mutation. These findings suggest that total JAK2 expression levels play a role in the biology of the disease in V617F-positive patients, and a therapy aiming at downmodulating the expression of the total JAK2 mRNA should be considered. In conclusion, we studied JAK2 total and V6217F mutant mRNA levels in plasma. We show high levels of JAK2 expression in MPD patients and these levels correlate with survival.
Collapse
Affiliation(s)
- W Ma
- Haematopathology Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Yeh C, Ma W, Kantarjian H, Zhang ZJ, Cortes J, Albitar M. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7028 Background: The major mechanism underlying imatinib resistance in patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with point mutations in the BCR-ABL tyrosine kinase. We describe three novel ABL premature termination mutations leading to BCR-ABL truncation in leukemia patients with multidrug (imatinib/nilotinib/dasatinib) resistance. Methods: Peripheral blood or bone marrow samples from drug-resistant CML patients were collected. Total nucleic acids were purified and subjected to two rounds of PCR analysis, with the first PCR designed to eliminate amplification of the wild-type, non-translocated ABL gene. Bi-directional sequencing was then performed. HL60 cells (a Ph-negative myeloid leukemia cell line) and peripheral blood of healthy subjects were used as negative controls; a human CML cell line (K562) was used as a positive control. Results: We identified an exon 7 deletion in three CML patients, a 4-nt insertion (908insCAGG) near the exon 5/6 junction in one CML case, and an exon 6 point mutation (997C>T) in one patient with acute lymphoblastic leukemia (ALL). These mutations all create premature stop codons and cause termination at residues 381, 315, and 333, respectively, leading to truncated proteins with only the first quarter of the kinase domain (P-loop) or lacking the C-terminus of ABL including the A-loop. Conclusions: These novel mutations, and the previously documented 35-nt insertion in exon 8, may constitute a new class of mutations that 1) cause truncation of the BCR-ABL kinase; (2) abolish the regulatory element in the ABL kinase domain and the downstream C-terminal region; and (3) confer significant drug resistance. [Table: see text]
Collapse
Affiliation(s)
- C. Yeh
- Quest Diagnostics Nichols Institute, San Juan Capistrano, CA; M. D. Anderson Cancer Center, Houston, TX
| | - W. Ma
- Quest Diagnostics Nichols Institute, San Juan Capistrano, CA; M. D. Anderson Cancer Center, Houston, TX
| | - H. Kantarjian
- Quest Diagnostics Nichols Institute, San Juan Capistrano, CA; M. D. Anderson Cancer Center, Houston, TX
| | - Z. J. Zhang
- Quest Diagnostics Nichols Institute, San Juan Capistrano, CA; M. D. Anderson Cancer Center, Houston, TX
| | - J. Cortes
- Quest Diagnostics Nichols Institute, San Juan Capistrano, CA; M. D. Anderson Cancer Center, Houston, TX
| | - M. Albitar
- Quest Diagnostics Nichols Institute, San Juan Capistrano, CA; M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
7
|
Richardson PG, Chanan-Khan A, Lonial S, Krishnan A, Carroll M, Alsina M, Albitar M, Berman D, Kaplita S, Anderson K. Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8503] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8503 Background: Tanespimycin (Tan) disrupts HSP90, a key molecular chaperone for signal transduction proteins critical to myeloma (MM) growth, survival and drug resistance. Preclinical data show anti-tumor synergy between Tan and bortezomib (Bz) and suggest Tan may be neuroprotective, including reversibility of Bz-induced peripheral neuropathy (PN). A phase I study of single agent Tan in advanced MM showed favorable tolerability and modest activity. Methods: 72 patients (pts) with relapsed/refractory MM received 0.7 - 1.3 mg/m2 Bz as IVB followed by 1-hr infusion of 100 -340 mg/m2 Tan on days 1, 4, 8,11 q 21d, with 42 pts receiving the highest dose of both drugs as part of a phase II expansion. Toxicities were assessed by CTCAE v3 and response by modified EBMT criteria. Results: Of 72 pts, 72% had IgG subtype with a median age of 60 yo. Median time since MM diagnosis was 50 mos with median of 5 (1–15) prior regimens. Prior treatments included stem cell transplant (69%), thalidomide (74%), Bz (69%), lenalidomide (28%) and Hsp90 inhibitors (13%). 58 pts with measurable disease were treated at 1 or 1.3 mg/m2 Bz. Response rates (≥ MR) were 41%, 20% and 14% in the Bz-naive, -pretreated and -refractory pts respectively. In the subgroup with 1–3 prior therapies and who were Bz-naive, the response rate was 56%. Median duration of response (DOR) for all pts with response (n=14) was 10.7 mos, including 3 Bz-refractory pts who had durable PR through mos 12, 22 and 28. 3 other pts remain in response through 24 mos. Of the 72 pts, the most frequent AEs were diarrhea (60%), nausea (49%), fatigue (49%), thrombocytopenia (40%) and AST elevation (28%), which proved manageable with dose reduction and supportive care. Most frequent G3–4 AEs included thrombocytopenia (25%), diarrhea, anemia and fatigue (7% each), as well as back pain and AST elevation (4% each). Only 21% of pts had G1–2 PN; no G3–4 PN was seen. Conclusions: Tan + Bz is active and well tolerated in relapsed/refractory MM, with durable responses in Bz-naive, -pretreated and -refractory pts. Median DOR for the combination compares favorably to Bz monotherapy. Final PFS data will be presented. No severe PN has been observed, consistent with Tan's neuroprotective effect in pre-clinical models. A phase III study of Tan + Bz vs Bz is ongoing. [Table: see text]
Collapse
Affiliation(s)
- P. G. Richardson
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - A. Chanan-Khan
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - S. Lonial
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - A. Krishnan
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - M. Carroll
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - M. Alsina
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - M. Albitar
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - D. Berman
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - S. Kaplita
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - K. Anderson
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| |
Collapse
|
8
|
Sanders HR, Li H, Qu KZ, Zhang ZJ, Sferruzza AD, Albitar M. Intragenic expression profile in tissue and plasma for the detection of TMPRSS2 rearrangements associated with prostate cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5162 Background: TMPRSS2 gene rearrangements have been reported in 40%-85% of prostate cancer (PCa) patients and have not been found in normal individuals or those with benign prostate hyperplasia (BPH). However, multiple partner genes, including ETS transcription genes, and breakpoints have been reported. We developed an assay based on TMPRSS2 5′ and 3′ intragenic differential expression (IDE) to potentially serve as a diagnostic or prognostic marker for PCa. Methods: We analyzed TMPRSS2 in FFPE tissue from 20 patients (9 PCa and 11 BPH) and plasma from 42 patients (32 PCa and 10 BPH). IDE was expressed as a ratio of 3′:5′ transcript levels which were determined by real-time RT-PCR using distinct primer/probe sets. A normal 3′:5′ ratio (≥30) was established by comparing nonmalignant cells to tumor cells from FFPE tissue. This cutoff was subsequently used to identify abnormal ratios in plasma specimens. Results: In FFPE tissue, 100% of PCa samples had a 3′:5′ratio <30 and 91% of BPH samples were ≥30 ( Table ). RNA in 48% of plasma samples passed our QC criteria for acceptability. The 3′:5′ ratios were <30 in 47% and ≥30 in 6.7% PCa plasma. Conclusions: By measuring IDE, we are not limited to screening for known TMPRSS2/ETS gene translocations. In tissue, this approach enabled us to identify patients with PCa vs. BPH with high specificity. Although work is needed to improve plasma RNA quality, IDE of plasma TMPRSS2 may be a useful non-invasive diagnostic or prognostic tool. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - H. Li
- Quest Diagnostics, San Juan Capistrano, CA
| | - K. Z. Qu
- Quest Diagnostics, San Juan Capistrano, CA
| | | | | | - M. Albitar
- Quest Diagnostics, San Juan Capistrano, CA
| |
Collapse
|
9
|
Bruey J, Kantarjian H, Ma W, Yeh C, Peralta R, Lee T, O'Brien S, Estrov Z, Cortes J, Albitar M. Alternatively spliced truncated BCR-ABL1 protein in CML patients with resistance to kinase inhibitors. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7026 Background: We have reported that some patients with imatinib-resistant chronic myeloid leukemia (CML) express an alternatively spliced BCR-ABL mRNA with a 35-bp insertion (BCR-ABL135INS), resulting in the addition of 10 residues and truncation of 653 residues. Molecular dynamic simulation suggested that this truncation and insertion of new 10 AA results in structural changes similar to those seen in BCR-ABL with T315I mutation. Here we evaluate the prevalence of BCR-ABL135INS in imatinib-resistant CML, examine the effect of this mutation on resistance to compared the efficiency of various kinase inhibitors in vitro, and suggest a model for persistent CML and a possible strategy to eradicate residual disease. Methods: Using a sensitive PCR method, we determined the prevalence of the alternatively spliced BCR-ABL135INS mRNA in 288 patients with chronic-phase CML resistant to imatinib. Expression of truncated protein was confirmed by Western blot. We then tested the effectiveness of various kinase inhibitors on human K562 CML cells expressing different levels of BCR-ABL135INS along with wild-type BCR-ABL1. Results: BCR-ABL135INS mRNA was detected in 210 (73%) of the 288 patients. Only 25% of BCR-ABL135INS positive cases showed coexistance of ABL1 kinase point mutation. Immunoprecipitation studies demonstrated that expression of the predicted 143-kD BCR-ABL135INS protein at levels proportional to those predicted by mRNA. Expression of BCR-ABL135INS in K562 cells was sufficient to conferred resistance to imatinib, dasatinib, and nilotinib in a dose-dependant fashion. However, no resistance was detected using aurora kinase inhibitor (MK 0457) or homoharringtonine (HHT). BCR-ABL135INS suppressed imatinib, nilotinib, and dasatinib-mediated dephosphorylation of CRKL, LYN, SRC, and STAT5, but had no effect on MK 0457-mediated dephosphorylation. The combination of imatinib with nilotinib or HHT showed strong synergy, overcoming BCR-ABL135INS-induced resistance in vitro. Conclusions: These findings emphasize the importance of the overlooked alternatively spliced BCR-ABL135INS protein and may provide a strategy to treat resistant disease and eradicate residual CML. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Bruey
- Quest Diagnostics INC, San Juan Capistrano, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Consortium for Bioinformatics, Minneapolis, MN
| | - H. Kantarjian
- Quest Diagnostics INC, San Juan Capistrano, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Consortium for Bioinformatics, Minneapolis, MN
| | - W. Ma
- Quest Diagnostics INC, San Juan Capistrano, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Consortium for Bioinformatics, Minneapolis, MN
| | - C. Yeh
- Quest Diagnostics INC, San Juan Capistrano, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Consortium for Bioinformatics, Minneapolis, MN
| | - R. Peralta
- Quest Diagnostics INC, San Juan Capistrano, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Consortium for Bioinformatics, Minneapolis, MN
| | - T. Lee
- Quest Diagnostics INC, San Juan Capistrano, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Consortium for Bioinformatics, Minneapolis, MN
| | - S. O'Brien
- Quest Diagnostics INC, San Juan Capistrano, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Consortium for Bioinformatics, Minneapolis, MN
| | - Z. Estrov
- Quest Diagnostics INC, San Juan Capistrano, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Consortium for Bioinformatics, Minneapolis, MN
| | - J. Cortes
- Quest Diagnostics INC, San Juan Capistrano, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Consortium for Bioinformatics, Minneapolis, MN
| | - M. Albitar
- Quest Diagnostics INC, San Juan Capistrano, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Consortium for Bioinformatics, Minneapolis, MN
| |
Collapse
|
10
|
Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol 2009; 31:97-105. [PMID: 18190591 PMCID: PMC4163781 DOI: 10.1111/j.1751-553x.2007.01010.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Syndecan-1 (sCD138) is a transmembrane heparan sulfate-bearing proteoglycan expressed in epithelial cells as well as hematopoietic cells that demonstrate plasmacytoid differentiation. Higher levels of sCD138 correlate with poor outcome in myeloma. We examined the association of circulating sCD138 levels in plasma with clinical behavior in 104 patients with chronic lymphocytic leukemia. sCD138 levels were significantly higher in patients (median, 52.8 ng/ml; range, 13.4-252.7 ng/ml) than in healthy control subjects (median, 19.86; range, 14.49-33.14 ng/ml) (P < 0.01). Elevated sCD138 (>median, 52.8 ng/ml) was associated with significantly shorter survival (P = 0.0004); this association was independent of IgVH mutation status, beta2-microglobulin (beta2-M) level, and treatment history. Patients with mutated IgVH but high sCD138 levels (>52.8 ng/ml) had significantly shorter survival than those with mutated IgVH and lower levels of sCD138. Similarly, patients with unmutated IgVH but high sCD138 levels had significantly shorter survival than those with lower sCD138 levels and unmutated IgVH (P = 0.007). In a multivariate Cox regression model, only Rai stage, beta2-M, and sCD138 remained predictors of survival. These data suggest that sCD138 when combined with beta2-M and Rai stage, may replace the need for testing IgVH mutation status.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
- Female
- Genetic Predisposition to Disease
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Male
- Middle Aged
- Mutation
- Predictive Value of Tests
- Prognosis
- Solubility
- Syndecan-1/blood
- Syndecan-1/genetics
Collapse
Affiliation(s)
- I Jilani
- Department of Hematology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H, O'Brien S, Giles F, Albitar M. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis. Cytometry B Clin Cytom 2007; 70:270-5. [PMID: 16906585 DOI: 10.1002/cyto.b.20134] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Lack of immunoglobulin heavy chain genes (IgV(H)) mutation in patients with chronic lymphocytic leukemia (CLL) is associated with rapid disease progression and shorter survival. The zeta-chain (T-cell receptor) associated protein kinase 70 kDa (ZAP-70) has been reported to be a surrogate marker for IgV(H) mutation status, and its expression in leukemic cells correlates with unmutated IgV(H). However, ZAP-70 detection by flow cytometry varies significantly dependant on the antibodies used, the method of performing the assay, and the condition of the cells in the specimen. The clinical value of ZAP-70 testing when samples are shipped under poorly controlled conditions is not known. Furthermore, testing in a research environment may differ from testing in a routine clinical laboratory. We validated an assay for ZAP-70 by comparing results with clinical outcome and the mutation status of the IgV(H). Using stored samples, we show significant correlation between ZAP-70 expression and clinical outcome as well as IgV(H) mutation at a cut-off point of 15%. While positive samples (>15% positivity) remain positive when kept in the laboratory environment for 48 h after initial testing, results obtained from samples from CLL patients tested after shipping at room temperature for routine testing showed no correlation with IgV(H) mutation status when 15% cut-off was used. In these samples, cut-point of 10% correlated with the IgV(H) mutation (P = 0.0001). This data suggests that although ZAP-70 positivity correlates with IgV(H) mutation status and survival, variations in sample handling and preparation may influence results. We show that IgV(H) mutation results, unlike ZAP-70 remain correlated with CD38 expression and beta-2 microglobulin in shipped samples, and ZAP-70 testing should not be used as the sole criterion for stratifying patients for therapy.
Collapse
Affiliation(s)
- M R Sheikholeslami
- Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA 92675, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Richardson PG, Chanan-Khan A, Lonial S, Krishnan A, Carroll M, Cropp GF, Albitar M, Johnson RG, Hannah A, Anderson K. Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3532] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3532 Background: Tanespimycin (17-AAG/KOS 953) disrupts Hsp90, a molecular chaperone of MM client proteins including IL-6 and IGF-1R that are key to MM growth, survival and drug resistance. Single agent T was well tolerated with modest anti- MM activity. Preclinical studies suggest potential synergy with BZ. Methods: Pts received BZ as IVB followed by 1-hr infusion of T on D1,4,8,11 q 21d. Results: 49 pts were enrolled in 7 cohorts (T 100- 340 mg/m2; BZ 0.7 - 1.3 mg/m2). PK of T was similar with or without BZ. Inhibition of 20S proteasome with T+BZ was not different vs. historical BZ single agent data. PBLs showed induction of Hsp70 4h post-infusion with maintenance of induction prior to T infusion across the dosing interval; pAKT plus total AKT were also reduced 4 and 72h following infusion. CD138 but not CD4 or CD8 cells from serial BM aspirates showed induction of apoptosis by flow cytometry. In addition, ↓expression of IGR-1R and IL-6R client proteins was seen after treatment. Safety: In Cohort 7, 19 pts received T 340 / BZ 1.3 mg/m2. Common all-grade (G) drug-related toxicity (n=19) included diarrhea (42%), nausea (32%), vomiting (26%), ↑ AST/ALT/Alk Phos (26%/21%/21%), myalgias (16%), and dizziness (16%). G3 thrombocytopenia was noted in 16% with no other G3 toxicity observed in more than 1 pt. DLT was seen in 2 pts: G3 myalgias/cramps and dehydration (reversible in both). G1–2 only treatment-emergent peripheral neuropathy was recorded in 15%. Activity: Responses have been seen across dose levels in BZ-naïve, pre-treated and ref pts (“ref” defined as no response to or disease progression within 60d of last dose of BZ-containing regimen). Specifically, 1 BZ-ref pt with 3 prior regimens had confirmed PR after 2 cycles and continues in Cycle 9 (M-spike ↓92%); a 2nd pt with 2 prior regimens achieved PR after 2 cycles and continues in Cycle 7; a 3rd pt with 7 prior regimens with confirmed PR after 3 cycles continues in Cycle 6. Conclusions: Treatment with T 340/ BZ 1.3 combination had generally manageable toxicity. Durable Hsp90 inhibition and similar proteasome inhibition (vs single-agent BZ) was seen. Importantly, anti-MM activity in BZ-ref pts was observed and further investigation of this combination in rel/ref MM is therefore warranted. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. G. Richardson
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Kosan Biosciences, Hayward, CA; Quest Hematopathology, San Juan Capistrano, CA
| | - A. Chanan-Khan
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Kosan Biosciences, Hayward, CA; Quest Hematopathology, San Juan Capistrano, CA
| | - S. Lonial
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Kosan Biosciences, Hayward, CA; Quest Hematopathology, San Juan Capistrano, CA
| | - A. Krishnan
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Kosan Biosciences, Hayward, CA; Quest Hematopathology, San Juan Capistrano, CA
| | - M. Carroll
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Kosan Biosciences, Hayward, CA; Quest Hematopathology, San Juan Capistrano, CA
| | - G. F. Cropp
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Kosan Biosciences, Hayward, CA; Quest Hematopathology, San Juan Capistrano, CA
| | - M. Albitar
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Kosan Biosciences, Hayward, CA; Quest Hematopathology, San Juan Capistrano, CA
| | - R. G. Johnson
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Kosan Biosciences, Hayward, CA; Quest Hematopathology, San Juan Capistrano, CA
| | - A. Hannah
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Kosan Biosciences, Hayward, CA; Quest Hematopathology, San Juan Capistrano, CA
| | - K. Anderson
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Kosan Biosciences, Hayward, CA; Quest Hematopathology, San Juan Capistrano, CA
| |
Collapse
|
13
|
Albitar M, Johnson M, Do KA, Day A, Jilani I, Pierce S, Estey E, Kantarjian H, Keating M, Verstovsek S, O'brien S, Giles FJ. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia 2007; 21:480-8. [PMID: 17215857 DOI: 10.1038/sj.leu.2404506] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
beta-2 Microglobulin (beta2M), a subunit of human leukocyte antigen-class I (HLA-I), is well established as a marker of prognosis in various solid tumors and hematologic malignancies. The prognostic role of intact free-circulating HLA-I (sHLA-I) is less well understood. We compared the clinical relevance of plasma levels of sHLA-I and beta2M in patients with acute myeloid leukemia (AML; n=209) or advanced myelodysplastic syndrome (MDS; n=98). sHLA-1 and beta2M levels were significantly higher in AML and MDS patients than in control subjects, but did not differ significantly between the two disease groups. In AML patients, multivariate analysis showed both sHLA-1 and beta2-M to be highly predictive of complete remission (CR), survival and duration of complete response (CRD). In MDS, the predictive value of the two markers differed substantially from one another: beta2M was associated with survival, CR and CRD, whereas sHLA-I was not. These findings not only establish the role of sHLA-I as a tumor marker in AML but also support that MDS is clinically and biologically distinct from AML. sHLA-I has been reported to be an immunomodulator inhibiting the cytotoxic effects of T-lymphocytes, which may offset its predictive value for disease aggressiveness in patients with MDS.
Collapse
Affiliation(s)
- M Albitar
- Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Ravandi F, Jilani I, Estey E, Kantarjian H, Dey A, Aguilar C, Jitkaroon C, Giles F, O'Brien S, Keating M, Albitar M. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). Leuk Res 2006; 31:791-7. [PMID: 17156841 DOI: 10.1016/j.leukres.2006.11.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2006] [Revised: 10/24/2006] [Accepted: 11/01/2006] [Indexed: 11/20/2022]
Abstract
FLT3 ligand (FL) has a significant role in the proliferation and differentiation of hematopoietic cells. Mutations in the FLT3 receptor gene have been reported in 30% of patients with AML. We investigated whether abnormal phosphorylation of FLT3 may be more common in AML. We evaluated FLT3 protein and its phosphorylation in the plasma from 85 patients with AML, 16 patients with myelodysplastic syndrome (MDS) and 5 patients with acute lymphoblastic leukemia (ALL). There were no significant differences in the level of plasma FLT3 protein level in the different diseases (p=0.57). AML patients had a significantly higher level of phospho-FLT3:FLT3 ratio (p=0.02). FLT3-ITD and FLT3 point mutations were present in 27 (32%) of the AML patients. Phosphorylated FLT3 was significantly higher in the plasma from patients with FLT3 mutation (p=0.002). Overall, there was no correlation between survival and the plasma level of FLT3 protein or its phosphorylated form. However, amongst the patients without FLT3 mutations, those with a higher level of phosphorylated FLT3 had a significantly shorter duration of remission (p=0.04). Other mechanisms may be responsible for abnormal phosphorylation of FLT3 and inhibitors of FLT3 should also be investigated in patients without mutations.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Cell Differentiation/genetics
- Cell Proliferation
- Female
- Hematopoietic Stem Cells
- Humans
- Leukemia, Myeloid, Acute/blood
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/mortality
- Leukemia, Myeloid, Acute/therapy
- Male
- Membrane Proteins/genetics
- Middle Aged
- Myelodysplastic Syndromes/blood
- Myelodysplastic Syndromes/genetics
- Myelodysplastic Syndromes/mortality
- Myelodysplastic Syndromes/therapy
- Phosphorylation
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
- Protein Processing, Post-Translational/genetics
- Remission Induction
- fms-Like Tyrosine Kinase 3/blood
- fms-Like Tyrosine Kinase 3/genetics
Collapse
Affiliation(s)
- F Ravandi
- Leukemia Department, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Jilani I, Keating M, Day A, William W, Kantarjian H, O'brien S, Giles FJ, Albitar M. Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies. ACTA ACUST UNITED AC 2006; 28:325-31. [PMID: 16999724 DOI: 10.1111/j.1365-2257.2006.00813.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Molecular response and monitoring of minimal residual disease (MRD) is becoming an essential part of most protocols for treating leukemia and lymphoma patients. Detection of abnormal clones by PCR analysis of complementarity determining regions (CDRs) in immunoglobulin genes is currently standard practice for diagnosis, but is not widely used to monitor MRD because of the low sensitivity of assays that use consensus primers. Use of specific primers can improve the sensitivity of the assay, but is a cumbersome, expensive, and time-consuming process. We developed a simple and cost-effective approach to detect MRD in B-cell malignancies that is usable in clinical laboratories. The new assay uses ligase chain reaction (LCR) to detect clonality. The sensitivity of the LCR assay is 1 per 500,000 cells, and it can detect all subclones that were present in the pretherapy diagnostic sample.
Collapse
Affiliation(s)
- I Jilani
- Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690-6130, USA
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Ma W, Jilani I, Gorre M, Keating M, Chan H, Tseng R, Kantarjian H, O'Brien S, Giles FJ, Albitar M. Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia. Br J Haematol 2006; 133:690-2. [PMID: 16704448 DOI: 10.1111/j.1365-2141.2006.06113.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
17
|
Ma W, Kantarjian H, Jilani I, Gorre M, Bhalla K, Ottmann O, Giles F, Albitar M. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. Leukemia 2006; 20:1989-91. [PMID: 16932346 DOI: 10.1038/sj.leu.2404355] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Most studies test for mutations in the kinase domain of the abl gene in chronic myeloid leukemia (CML) using peripheral blood (PB) cells. Frequently, progression of the disease manifests with increased blasts in bone marrow (BM) and not in PB. Simultaneous analysis of plasma, PB cells and BM cells from 41 imatinib-resistant CML patients showed mutations in 63% of PB cells and 68% of plasma or BM cells (P = 0.04). In discordant patients, 13 mutations were detected in plasma, 11 in BM cells and 9 in PB cells. The T315I mutation was detected in plasma and BM but not PB cells in one patient. We detected no mutations in the plasma of 45 previously untreated CML patients, but two of these patients showed mutations in plasma and not cells by 9 months on therapy. Circulating plasma mRNA is a reliable alternative to BM mRNA for detecting ABL mutations.
Collapse
MESH Headings
- Antineoplastic Agents/therapeutic use
- Benzamides
- Drug Monitoring/methods
- Drug Resistance, Neoplasm
- Fusion Proteins, bcr-abl/genetics
- Genetic Heterogeneity
- Genetic Testing/methods
- Genetic Testing/standards
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Mutation
- Piperazines/therapeutic use
- Plasma
- Pyrimidines/therapeutic use
- RNA, Messenger/blood
- RNA, Messenger/isolation & purification
- Reproducibility of Results
- Sensitivity and Specificity
Collapse
Affiliation(s)
- W Ma
- Department of Hematology, Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA 92690-6130, USA
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Ma W, Kantarjian H, Verstovsek S, Jilani I, Gorre M, Giles F, Cortes J, O'Brien S, Keating M, Albitar M. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Br J Haematol 2006; 134:341-3. [PMID: 16787500 DOI: 10.1111/j.1365-2141.2006.06174.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
19
|
Ferrajoli A, O’Brien S, Faderl S, Wierda WG, Schlette E, Jorgensen JL, Reuben JM, Albitar M, Keating MJ. The combination of rituximab and GM-CSF in elderly patients with chronic lymphocytic leukemia (CLL). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.6602] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6602 Background: CLL is a disease found more frequently in the elderly (50% of the patients are age ≥70 at diagnosis). Nevertheless treatment startegies for elderly patients have not been optimized. Elderly patients are often excluded from chemotherapy programs because of fear of severe toxicities resulting from myelosuppression. Therefore, we explored the activity of rituximab in combination with GM-CSF in elderly patients with CLL. The rationale for this combination stems from in vitro data showing increased activity of rituximab when administered togheter with GM-CSF (Venugopal P. Leuk. Res.2000). Methods: Patients age ≥70 years, untreated or previously treated, were eligible if they had indications for treatment (NCI-WG criteria). Treatment consisted of rituximab 375 mg/m2 administered weekly for 4 weeks and GM-CSF 250 mcg s.q. three times weekly for 8 weeks. In the first week GM-CSF was given on day 1 and 3 and rituximab was given on day 4. Genomic aberrations, IgVH mutation status, ZAP-70 and CD38 expression were evaluated prospectively. Correlative studies measured changes in cell surface and soluble CD20, apoptosis and quality of life (FACT-An V4). Results: 39 patients have been enrolled, 28 are evaluable for response and 31 for toxicity. According to NCI criteria the OR rate was 61%. 7% of the patients achieved CR, 11% nodular PR and 43% PR. Thirty patients are alive and the median time to treatment failure has not been reached with a median follow up of 5 months. Toxicity attributable to GM-CSF was G1 injection site reaction observed in 16% of the patients. OR rates were higher in naive than in previously treated patients (74% vs 46%), in patients with favorable genomic features (73% vs 40%) and mutated IgVH (89%vs 44%). No difference in OR was found in patients expressing high or low CD38 (60% vs 55%). Upregulation of surface CD20, measured 24h after the 2nd dose of GM-CSF, was observed in 3 out of 4 patients studied. Fatigue level was reduced by a mean of 7 points according to the FACT-An scale (6 patients). Conclusions: Treatment with rituximab and GM-CSF induced a high response rate with minimal toxicity in elderly patients with CLL. Priming with GM-CSF resulted in increased expression of surface CD20. This combination of rituximab and GM-CSF improved systemic symptoms such as fatigue. [Table: see text]
Collapse
Affiliation(s)
- A. Ferrajoli
- UT M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - S. O’Brien
- UT M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - S. Faderl
- UT M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - W. G. Wierda
- UT M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - E. Schlette
- UT M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - J. L. Jorgensen
- UT M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - J. M. Reuben
- UT M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - M. Albitar
- UT M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - M. J. Keating
- UT M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| |
Collapse
|
20
|
Chanan-Khan A, Richardson P, Alsina M, Lonial S, Krishnan A, Carroll M, Albitar M, Hannah AL, Johnson RG, Anderson K. Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3066] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3066 Background: KOS-953 (17-AAG in Cremophor) inhibits HSP90 chaperone function, resulting in disruption of protein complexes and proteasomal degradation. Single-agent 17-AAG is active in relapsed/refractory MM patients (pts) (ASH 2005 A#361), with a recommended dose ≥ 275 mg/m2. In vitro, BZ + KOS-953 show additive cytotoxicity of myeloma cells. Objectives: Define phase 2 dose of BZ+KOS-953 in pts with relapsed refractory MM. Determine PK of KOS-953 and its active metabolite. Evaluate proteasome inhibition in whole blood lysates and explore changes in intracellular signaling proteins in pt PBMCs and MM cells. Methods: Pts received BZ as IV bolus followed by 1-hour infusion KOS-953 twice weekly for 2 out of 3 weeks. Dose escalation occurred in a step-wise manner. PK and collection of surrogates are performed following the 1st and 4th infusion. Pts assessed for response by EBMT criteria. Results: 20 pts were enrolled in 4 cohorts: BZ+KOS-953 (mg/m2): 0.7+100 (n=3); 1.0+100 (n=3); 1.0+150 (n=8); and 1.3+150 (n=6), receiving a total of 103+ cycles (median 5 cycles; range <1 - 17). Demographics: 10F/10M; median age/KPS 64y/90; median # of prior regimens 4 (range 2–16); 75% prior BZ (5 with ≥2 prior BZ); 95% prior thalidomide; 15% prior lenalidomide; 70% prior SCT(s). DLT observed in Cohort 2 (n=1 grade 4 hepatotoxicity in a setting of congestive heart failure secondary to cardiac amyloidosis) and in Cohort 3 (n=1 pancreatitis). Other Grade 3–4 toxicity (1 each): thrombocytopenia with Herpes Zoster recurrence and pneumonia; septic thrombophlebitis. Drug-related toxicity (mild-to-moderate): diarrhea (n=8), fatigue (n=8), constipation (n=7), neuropathy (n=7), ↑AST (n=5), muscle cramps (n=5) and rash (n=4). PK similar to single-agent trial; stationary kinetics noted upon twice weekly dosing. 20S proteasome function (1.3 mg/m2, end of infusion): 50% decrease (similar to predicted values). Response was seen in 6 out of 12 BZ-refractory patients (1 nCR, 5 MR) and 3 out of 4 BZ-naïve pts (1 nCR, 2 MR). Conclusions: Dose escalation continues with no additive toxicity or PK interactions to date. Similar inhibition of the 20S proteasome is observed compared to BZ alone. Encouraging activity is seen in both BZ-naïve and BZ-refractory heavily pre-treated MM pts. [Table: see text]
Collapse
Affiliation(s)
- A. Chanan-Khan
- Roswell Park Cancer Institute, Buffalo, NY; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center, Tampa, FL; Winship Cancer Institute, Atlanta, GA; City of Hope, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Inc., Hayward, CA
| | - P. Richardson
- Roswell Park Cancer Institute, Buffalo, NY; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center, Tampa, FL; Winship Cancer Institute, Atlanta, GA; City of Hope, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Inc., Hayward, CA
| | - M. Alsina
- Roswell Park Cancer Institute, Buffalo, NY; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center, Tampa, FL; Winship Cancer Institute, Atlanta, GA; City of Hope, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Inc., Hayward, CA
| | - S. Lonial
- Roswell Park Cancer Institute, Buffalo, NY; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center, Tampa, FL; Winship Cancer Institute, Atlanta, GA; City of Hope, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Inc., Hayward, CA
| | - A. Krishnan
- Roswell Park Cancer Institute, Buffalo, NY; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center, Tampa, FL; Winship Cancer Institute, Atlanta, GA; City of Hope, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Inc., Hayward, CA
| | - M. Carroll
- Roswell Park Cancer Institute, Buffalo, NY; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center, Tampa, FL; Winship Cancer Institute, Atlanta, GA; City of Hope, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Inc., Hayward, CA
| | - M. Albitar
- Roswell Park Cancer Institute, Buffalo, NY; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center, Tampa, FL; Winship Cancer Institute, Atlanta, GA; City of Hope, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Inc., Hayward, CA
| | - A. L. Hannah
- Roswell Park Cancer Institute, Buffalo, NY; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center, Tampa, FL; Winship Cancer Institute, Atlanta, GA; City of Hope, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Inc., Hayward, CA
| | - R. G. Johnson
- Roswell Park Cancer Institute, Buffalo, NY; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center, Tampa, FL; Winship Cancer Institute, Atlanta, GA; City of Hope, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Inc., Hayward, CA
| | - K. Anderson
- Roswell Park Cancer Institute, Buffalo, NY; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center, Tampa, FL; Winship Cancer Institute, Atlanta, GA; City of Hope, Duarte, CA; Arizona Cancer Center, Tucson, AZ; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Inc., Hayward, CA
| |
Collapse
|
21
|
Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, Kantarjian HM, O'Brien SM, Jilani I, Albitar M. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia 2005; 19:1567-72. [PMID: 16049515 DOI: 10.1038/sj.leu.2403876] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Determining the percentage of peripheral blood (PB) and bone marrow (BM) blasts is important for diagnosing and classifying acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Although most patients with acute leukemia or MDS have a higher percentage of BM blasts than PB blasts, the relative proportion is reversed in some patients. We explored the clinical relevance of this phenomenon in MDS (n = 446), AML (n = 1314), and acute lymphoblastic leukemia (ALL) (n = 385). Among patients with MDS or ALL, but not AML, having a higher blast percentage in PB than in BM was associated with significantly shorter survival. In multivariate analyses, these associations were independent of other relevant predictors, including cytogenetic status. Our findings suggest that MDS and ALL patients who have a higher percentage of PB blasts than BM blasts have more aggressive disease. These data also suggest that MDS classification schemes should take into account the percentage of blasts in PB differently from the percentage of blasts in BM.
Collapse
Affiliation(s)
- H M Amin
- Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Ottmann O, Giles F, Wassmann B, Hochhaus A, Rae P, Beran M, Albitar M, Alland L, Dugan M, Kantarjian H. Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant bcr-abl positive lymphoid malignancies. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3015] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- O. Ottmann
- J. W. Goethe Univ, Frankfurt, Germany; UT M.D. Anderson Cancer Ctr, Houston, TX; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - F. Giles
- J. W. Goethe Univ, Frankfurt, Germany; UT M.D. Anderson Cancer Ctr, Houston, TX; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - B. Wassmann
- J. W. Goethe Univ, Frankfurt, Germany; UT M.D. Anderson Cancer Ctr, Houston, TX; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - A. Hochhaus
- J. W. Goethe Univ, Frankfurt, Germany; UT M.D. Anderson Cancer Ctr, Houston, TX; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - P. Rae
- J. W. Goethe Univ, Frankfurt, Germany; UT M.D. Anderson Cancer Ctr, Houston, TX; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - M. Beran
- J. W. Goethe Univ, Frankfurt, Germany; UT M.D. Anderson Cancer Ctr, Houston, TX; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - M. Albitar
- J. W. Goethe Univ, Frankfurt, Germany; UT M.D. Anderson Cancer Ctr, Houston, TX; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - L. Alland
- J. W. Goethe Univ, Frankfurt, Germany; UT M.D. Anderson Cancer Ctr, Houston, TX; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - M. Dugan
- J. W. Goethe Univ, Frankfurt, Germany; UT M.D. Anderson Cancer Ctr, Houston, TX; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - H. Kantarjian
- J. W. Goethe Univ, Frankfurt, Germany; UT M.D. Anderson Cancer Ctr, Houston, TX; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| |
Collapse
|
23
|
Mitsiades C, Chanan-Khan A, Alsina M, Doss D, Landrigan B, Kettner D, Albitar M, Cropp GF, Hannah AL, Richardson P. Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3056] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Mitsiades
- Dana-Farber Cancer Ctr, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffitt Cancer Ctr, Tampa, FL; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - A. Chanan-Khan
- Dana-Farber Cancer Ctr, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffitt Cancer Ctr, Tampa, FL; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - M. Alsina
- Dana-Farber Cancer Ctr, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffitt Cancer Ctr, Tampa, FL; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - D. Doss
- Dana-Farber Cancer Ctr, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffitt Cancer Ctr, Tampa, FL; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - B. Landrigan
- Dana-Farber Cancer Ctr, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffitt Cancer Ctr, Tampa, FL; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - D. Kettner
- Dana-Farber Cancer Ctr, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffitt Cancer Ctr, Tampa, FL; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - M. Albitar
- Dana-Farber Cancer Ctr, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffitt Cancer Ctr, Tampa, FL; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - G. F. Cropp
- Dana-Farber Cancer Ctr, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffitt Cancer Ctr, Tampa, FL; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - A. L. Hannah
- Dana-Farber Cancer Ctr, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffitt Cancer Ctr, Tampa, FL; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - P. Richardson
- Dana-Farber Cancer Ctr, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffitt Cancer Ctr, Tampa, FL; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| |
Collapse
|
24
|
Kantarjian H, Ottmann O, Cortes J, Wassmann B, Jones D, Hochhaus A, Alland L, Dugan M, Albitar M, Giles F. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3014] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Kantarjian
- UT M.D. Anderson Cancer Ctr, Houston, TX; J. W. Goethe Univ, Frankfurt, Germany; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - O. Ottmann
- UT M.D. Anderson Cancer Ctr, Houston, TX; J. W. Goethe Univ, Frankfurt, Germany; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - J. Cortes
- UT M.D. Anderson Cancer Ctr, Houston, TX; J. W. Goethe Univ, Frankfurt, Germany; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - B. Wassmann
- UT M.D. Anderson Cancer Ctr, Houston, TX; J. W. Goethe Univ, Frankfurt, Germany; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - D. Jones
- UT M.D. Anderson Cancer Ctr, Houston, TX; J. W. Goethe Univ, Frankfurt, Germany; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - A. Hochhaus
- UT M.D. Anderson Cancer Ctr, Houston, TX; J. W. Goethe Univ, Frankfurt, Germany; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - L. Alland
- UT M.D. Anderson Cancer Ctr, Houston, TX; J. W. Goethe Univ, Frankfurt, Germany; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - M. Dugan
- UT M.D. Anderson Cancer Ctr, Houston, TX; J. W. Goethe Univ, Frankfurt, Germany; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - M. Albitar
- UT M.D. Anderson Cancer Ctr, Houston, TX; J. W. Goethe Univ, Frankfurt, Germany; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| | - F. Giles
- UT M.D. Anderson Cancer Ctr, Houston, TX; J. W. Goethe Univ, Frankfurt, Germany; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA
| |
Collapse
|
25
|
Cortes J, Giles F, Salvado A, Sams I, Hohneker J, Albitar M, Powell B, Goldberg S, Kantarjian H. High-dose (HD) imatinib in patients (pts) with previously untreated chronic myeloid leukemia (CML) in early chronic phase (CP): preliminary results of a multicenter community based trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6518] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. Cortes
- MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Quest Diagnostics, Northridge, CA; Wake Forest Univ Comprehensive Cancer Ctr, Winston-Salem, NC; Hackensack Univ Medcl Ctr, Hackensack, NJ
| | - F. Giles
- MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Quest Diagnostics, Northridge, CA; Wake Forest Univ Comprehensive Cancer Ctr, Winston-Salem, NC; Hackensack Univ Medcl Ctr, Hackensack, NJ
| | - A. Salvado
- MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Quest Diagnostics, Northridge, CA; Wake Forest Univ Comprehensive Cancer Ctr, Winston-Salem, NC; Hackensack Univ Medcl Ctr, Hackensack, NJ
| | - I. Sams
- MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Quest Diagnostics, Northridge, CA; Wake Forest Univ Comprehensive Cancer Ctr, Winston-Salem, NC; Hackensack Univ Medcl Ctr, Hackensack, NJ
| | - J. Hohneker
- MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Quest Diagnostics, Northridge, CA; Wake Forest Univ Comprehensive Cancer Ctr, Winston-Salem, NC; Hackensack Univ Medcl Ctr, Hackensack, NJ
| | - M. Albitar
- MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Quest Diagnostics, Northridge, CA; Wake Forest Univ Comprehensive Cancer Ctr, Winston-Salem, NC; Hackensack Univ Medcl Ctr, Hackensack, NJ
| | - B. Powell
- MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Quest Diagnostics, Northridge, CA; Wake Forest Univ Comprehensive Cancer Ctr, Winston-Salem, NC; Hackensack Univ Medcl Ctr, Hackensack, NJ
| | - S. Goldberg
- MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Quest Diagnostics, Northridge, CA; Wake Forest Univ Comprehensive Cancer Ctr, Winston-Salem, NC; Hackensack Univ Medcl Ctr, Hackensack, NJ
| | - H. Kantarjian
- MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Quest Diagnostics, Northridge, CA; Wake Forest Univ Comprehensive Cancer Ctr, Winston-Salem, NC; Hackensack Univ Medcl Ctr, Hackensack, NJ
| |
Collapse
|
26
|
Feldman E, Giles F, Roboz G, Yee K, Curcio T, Rivera VM, Albitar M, Laliberte R, Bedrosian CL. A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6631] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Feldman
- Weill Cornell Medcl Ctr, New York, NY; UT MD Anderson Cancer Ctr, Houston, TX; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Quest Diagnostics, Inc., San Juan Capistrano, CA
| | - F. Giles
- Weill Cornell Medcl Ctr, New York, NY; UT MD Anderson Cancer Ctr, Houston, TX; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Quest Diagnostics, Inc., San Juan Capistrano, CA
| | - G. Roboz
- Weill Cornell Medcl Ctr, New York, NY; UT MD Anderson Cancer Ctr, Houston, TX; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Quest Diagnostics, Inc., San Juan Capistrano, CA
| | - K. Yee
- Weill Cornell Medcl Ctr, New York, NY; UT MD Anderson Cancer Ctr, Houston, TX; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Quest Diagnostics, Inc., San Juan Capistrano, CA
| | - T. Curcio
- Weill Cornell Medcl Ctr, New York, NY; UT MD Anderson Cancer Ctr, Houston, TX; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Quest Diagnostics, Inc., San Juan Capistrano, CA
| | - V. M. Rivera
- Weill Cornell Medcl Ctr, New York, NY; UT MD Anderson Cancer Ctr, Houston, TX; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Quest Diagnostics, Inc., San Juan Capistrano, CA
| | - M. Albitar
- Weill Cornell Medcl Ctr, New York, NY; UT MD Anderson Cancer Ctr, Houston, TX; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Quest Diagnostics, Inc., San Juan Capistrano, CA
| | - R. Laliberte
- Weill Cornell Medcl Ctr, New York, NY; UT MD Anderson Cancer Ctr, Houston, TX; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Quest Diagnostics, Inc., San Juan Capistrano, CA
| | - C. L. Bedrosian
- Weill Cornell Medcl Ctr, New York, NY; UT MD Anderson Cancer Ctr, Houston, TX; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Quest Diagnostics, Inc., San Juan Capistrano, CA
| |
Collapse
|
27
|
Albitar M, Cortes J, Giles F, Ma W, Kantarjian H, Salvado A, Sams I, Goldberg S, Bayard Powell B, Radich J. Molecular monitoring of chronic phase chronic myeloid leukemia patients treated with 800 mg imatinib. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Albitar
- Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA; MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Northern Jersey Cancer Assoc, Hackensack, NJ; Wake Forest Univ Cancer Ctr, Winston-Salem, NC; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - J. Cortes
- Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA; MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Northern Jersey Cancer Assoc, Hackensack, NJ; Wake Forest Univ Cancer Ctr, Winston-Salem, NC; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - F. Giles
- Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA; MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Northern Jersey Cancer Assoc, Hackensack, NJ; Wake Forest Univ Cancer Ctr, Winston-Salem, NC; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - W. Ma
- Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA; MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Northern Jersey Cancer Assoc, Hackensack, NJ; Wake Forest Univ Cancer Ctr, Winston-Salem, NC; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - H. Kantarjian
- Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA; MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Northern Jersey Cancer Assoc, Hackensack, NJ; Wake Forest Univ Cancer Ctr, Winston-Salem, NC; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - A. Salvado
- Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA; MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Northern Jersey Cancer Assoc, Hackensack, NJ; Wake Forest Univ Cancer Ctr, Winston-Salem, NC; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - I. Sams
- Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA; MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Northern Jersey Cancer Assoc, Hackensack, NJ; Wake Forest Univ Cancer Ctr, Winston-Salem, NC; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - S. Goldberg
- Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA; MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Northern Jersey Cancer Assoc, Hackensack, NJ; Wake Forest Univ Cancer Ctr, Winston-Salem, NC; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - B. Bayard Powell
- Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA; MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Northern Jersey Cancer Assoc, Hackensack, NJ; Wake Forest Univ Cancer Ctr, Winston-Salem, NC; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - J. Radich
- Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA; MD Anderson Cancer Ctr, Houston, TX; Novartis Pharmaceuticals, East Hanover, NJ; Northern Jersey Cancer Assoc, Hackensack, NJ; Wake Forest Univ Cancer Ctr, Winston-Salem, NC; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| |
Collapse
|
28
|
Chanan-Khan A, Alsina M, Carroll M, Landrigan B, Doss D, Albitar M, Mitsiades C, Cropp GF, Hannah AL, Richardson PG. Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6682] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Chanan-Khan
- Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffett, Tampa, FL; Arizona Cancer Ctr, Tucson, AZ; Dana-Farber Cancer Inst, Boston, MA; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - M. Alsina
- Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffett, Tampa, FL; Arizona Cancer Ctr, Tucson, AZ; Dana-Farber Cancer Inst, Boston, MA; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - M. Carroll
- Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffett, Tampa, FL; Arizona Cancer Ctr, Tucson, AZ; Dana-Farber Cancer Inst, Boston, MA; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - B. Landrigan
- Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffett, Tampa, FL; Arizona Cancer Ctr, Tucson, AZ; Dana-Farber Cancer Inst, Boston, MA; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - D. Doss
- Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffett, Tampa, FL; Arizona Cancer Ctr, Tucson, AZ; Dana-Farber Cancer Inst, Boston, MA; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - M. Albitar
- Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffett, Tampa, FL; Arizona Cancer Ctr, Tucson, AZ; Dana-Farber Cancer Inst, Boston, MA; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - C. Mitsiades
- Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffett, Tampa, FL; Arizona Cancer Ctr, Tucson, AZ; Dana-Farber Cancer Inst, Boston, MA; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - G. F. Cropp
- Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffett, Tampa, FL; Arizona Cancer Ctr, Tucson, AZ; Dana-Farber Cancer Inst, Boston, MA; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - A. L. Hannah
- Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffett, Tampa, FL; Arizona Cancer Ctr, Tucson, AZ; Dana-Farber Cancer Inst, Boston, MA; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| | - P. G. Richardson
- Roswell Park Cancer Institute, Buffalo, NY; H. Lee Moffett, Tampa, FL; Arizona Cancer Ctr, Tucson, AZ; Dana-Farber Cancer Inst, Boston, MA; Quest Diagnostics, San Juan Capistrano, CA; Kosan Biosciences, Hayward, CA
| |
Collapse
|
29
|
Sun X, Amin HM, Freireich EJ, Keating MJ, Kantarjian HM, Koller CA, O'Brien SM, Giles F, Albitar M. Hairy cell leukemia with large cells: long disease course with adequate response to therapy. Leukemia 2004; 18:1912-4. [PMID: 15385931 DOI: 10.1038/sj.leu.2403506] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
30
|
Wang XS, Giralt S, Warneke CL, Mendoza TR, Albitar M, Brown JO, Anderson KO, Cleeland CS. Longitudinal assessment of IL-6 and symptom severity in multiple myeloma patients during first 30 days of autologous BMT. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- X. S. Wang
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - S. Giralt
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - C. L. Warneke
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - T. R. Mendoza
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - M. Albitar
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - J. O. Brown
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - K. O. Anderson
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - C. S. Cleeland
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| |
Collapse
|
31
|
Khouri IF, Albitar M, Saliba RM, Ippoliti C, Ma YC, Keating MJ, Champlin RE. Low-dose alemtuzumab (Campath®) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant 2004; 33:833-7. [PMID: 14755312 DOI: 10.1038/sj.bmt.1704435] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Alemtuzumab is effective in reducing the risk of acute graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (ASCT). Alemtuzumab may also delay immune reconstitution and reduce graft-versus-leukemia effects. The optimal dose has not been established. We investigated engraftment, acute GVHD incidence and severity, and pharmacokinetics of alemtuzumab associated with the use of low-dose alemtuzumab/cyclophosphamide/total body irradiation and ASCT for patients with aggressive CD52-positive hematologic malignancies. In all, 12 patients were treated. Alemtuzumab 10 mg daily on days -7 to -3 was given intravenously. Tacrolimus and methotrexate were used for GVHD prophylaxis. Alemtuzemab was not detected in any of the 36 sequential serum samples tested between days -1 and +21 of transplant. All patients engrafted rapidly; the median time to an absolute neutrophil count >0.5 x 10(9)/l was 14 days (range 11-17 days), and the median time to a platelet count >20 x 10(9)/l was 16 days (range 6-30 days). By 1 month after transplant, nine patients had 100% donor chimerism, while three had mixed donor chimerism. At 3 months, 11 had achieved 100% donor chimerism. No cases of grade III/IV acute GVHD occurred. At a median follow-up interval of 14.7 months (range 4-24), seven patients remained alive, and five remained free of disease.
Collapse
Affiliation(s)
- I F Khouri
- Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | |
Collapse
|
32
|
Carew JS, Zhou Y, Albitar M, Carew JD, Keating MJ, Huang P. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 2003; 17:1437-47. [PMID: 12886229 DOI: 10.1038/sj.leu.2403043] [Citation(s) in RCA: 137] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Mitochondrial DNA (mtDNA) codes for 13 respiratory chain subunits and is more vulnerable to damage than nuclear DNA due, in part, to a lack of histone protection and a weak repair capacity. While mtDNA alterations have been observed in human cancer, their roles in oncogenesis and chemosensitivity remain unclear. We investigated the relationship between mtDNA mutations, reactive oxygen species (ROS) generation, and clinical outcomes in chronic lymphocytic leukemia (CLL) patients. An analysis of mtDNA from 20 CLL patients revealed that primary CLL cells from patients with prior chemotherapy had a significantly higher frequency of heteroplasmic mutations than did those from untreated patients. Overall, mtDNA mutations appeared to be associated with increased ROS generation. Patients refractory to conventional therapeutic agents tended to have higher mutation rates than patients who responded to treatment. Analysis of paired blood samples from the same patient led to the identification of a heteroplasmic mutation in the cytochrome c oxidase II gene several months after chemotherapy. The mutation was associated with increased ROS generation. Our results suggest for the first time that chemotherapy with DNA-damaging agents may cause mtDNA mutations in primary leukemia cells, which often exist in heteroplasmy, and are associated with increased ROS generation.
Collapse
MESH Headings
- Adult
- Aged
- Antineoplastic Agents/adverse effects
- Antineoplastic Agents/therapeutic use
- DNA Mutational Analysis
- DNA, Mitochondrial/genetics
- Electron Transport Complex IV/genetics
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Middle Aged
- Mutation
- Reactive Oxygen Species/metabolism
- Superoxides/metabolism
- Treatment Outcome
Collapse
Affiliation(s)
- J S Carew
- Department of Molecular Pathology, the University of Texas MD. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | |
Collapse
|
33
|
Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 2003; 17:1100-3. [PMID: 12764375 DOI: 10.1038/sj.leu.2402958] [Citation(s) in RCA: 163] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Granulocytic sarcoma (GS) is an extramedullary tumor composed of immature myeloid cells. The objectives of this study were to describe the frequency, presenting characteristics, and survival in patients with nonleukemic GS by conducting a review of all untreated patients presenting to the MD Anderson Cancer Center between January 1990 and June 2002. In all, 21 patients with nonleukemic GS, 1520 patients with acute myeloid leukemia (AML), and 402 patients with high-risk myelodysplastic syndrome (MDS) were identified. GS occurred in 1.4% of patients with AML, and 1.1% of patients with AML or high-risk MDSs. The median patient age was 57 years (range, 7-81). Among 20 patients with available cytogenetics in tissue and/or bone marrow, six had chromosome 8 abnormalities. The median follow-up of surviving patients is 12 months (range, 7-75). In all, 20 patients were treated. Patients were treated with AML-type chemotherapy (n=16), chemotherapy and radiotherapy (n=3), or radiotherapy alone (n=1). A total of 13 patients (65%) achieved complete remission and one patient (5%) achieved partial remission. The median overall survival was 20 months (range, 1-75), median overall failure-free survival was 12 months (range, 1-75). The median survival of patients with chromosome 8 abnormalities was 12 months compared with 40 months of those without (P=0.17). Novel therapies for patients with GS are required.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Child
- Chromosome Aberrations
- Chromosomes, Human, Pair 8/genetics
- Combined Modality Therapy
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/mortality
- Leukemia, Myeloid, Acute/therapy
- Male
- Middle Aged
- Myelodysplastic Syndromes/genetics
- Myelodysplastic Syndromes/mortality
- Myelodysplastic Syndromes/therapy
- Remission Induction
- Sarcoma, Myeloid/drug therapy
- Sarcoma, Myeloid/genetics
- Sarcoma, Myeloid/mortality
- Sarcoma, Myeloid/radiotherapy
- Survival Rate
- Treatment Outcome
Collapse
Affiliation(s)
- A-M Tsimberidou
- Department of Leukemia, The University of Texas, MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Jilani I, Estey E, Manshuri T, Caligiuri M, Keating M, Giles F, Thomas D, Kantarjian H, Albitar M. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia 2003; 17:114-9. [PMID: 12529667 DOI: 10.1038/sj.leu.2402743] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2002] [Accepted: 07/18/2002] [Indexed: 11/09/2022]
Abstract
Somatic mutation of the FLT3 gene as an internal tandem duplication (ITD) of the juxtamembrane domain-coding sequence causes constitutive tyrosine phosphorylation and activation. Tumor-specific DNA has been documented in the sera of patients with solid tumors even when it is in an early stage. We compared the detection of FLT3 ITD in DNA extracted from cells of bone marrow (BM) aspirations with DNA extracted from peripheral blood (PB) plasma in patients newly diagnosed with acute myeloid leukemia (AML; 85 patients), myelodysplastic syndrome (MDS; 16 patients), and acute lymphocytic leukemia (ALL; 16 patients). FLT3 ITD was detected in 18 (21%) AML samples and in one (6%) MDS sample in both cellular and plasma DNA but in none of the ALL samples. Hemizygous/homozygous FLT3 ITD was detected in five (28%) of the FLT3 ITD-positive AML using plasma DNA, whereas only four of these cases showed hemizygous/homozygous FLT3 ITD using cellular DNA. The presence of FLT3 ITD was associated with significantly shorter survival (P = 0.02) when only patients younger than 50 years of age (48 AML+MDS patients) were considered. This finding was independent of cytogenetics in this age group. However, patients with the FLT3 ITD hemizygous/homozygous phenotype had even shorter survival (P = <0.001). As expected, the presence of FLT3 ITD correlated with higher white blood cell (WBC) counts. These data demonstrate that plasma DNA is a reliable alternative resource for detecting FLT3ITD, especially the hemizygous/homozygous genotype. Furthermore, the data derived from this study support the notion that the presence of FLT3 ITD in conjunction with the absence of the wild-type FLT3 allele predicts an especially poor prognosis for patients with AML.
Collapse
Affiliation(s)
- I Jilani
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Huh YO, Jilani I, Estey E, Giles F, Kantarjian H, Freireich E, Albitar M. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Leukemia 2002; 16:2249-52. [PMID: 12399969 DOI: 10.1038/sj.leu.2402704] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2002] [Accepted: 06/20/2002] [Indexed: 11/09/2022]
Abstract
Refractory anemia with excess blasts in transformation (RAEB-T) is a subgroup of myelodysplastic syndrome (MDS) in which the bone marrow blast count ranges from 20% to 30%. The recently proposed World Health Organization Classification of Hematologic Malignancies eliminated this category from MDS by lowering the blast count cutoff for acute myeloid leukemia (AML) from 30% to 20%. However, MDS is distinguished from AML by a significant increase in apoptosis. To investigate the difference in apoptosis between RAEB-T, AML, and other categories of MDS, we prospectively analyzed fresh bone marrow samples using the Annexin V and mitochondrial potential assays. There was a significantly higher level of apoptosis in RAEB-T than in AML according to both assays, while no significant differences between RAEB-T and other categories of MDS were noted. The data suggest that RAEB-T is more likely to be an advanced stage of MDS and biologically different from AML.
Collapse
Affiliation(s)
- Y O Huh
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | |
Collapse
|
36
|
Albitar M, Estey E. Response to Drs Rowe and Bown. Leukemia 2002. [DOI: 10.1038/sj.leu.2402668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
37
|
Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, Garcia-Manero G, Manshouri T, Albitar M. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002; 16:1045-52. [PMID: 12040436 DOI: 10.1038/sj.leu.2402540] [Citation(s) in RCA: 95] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2001] [Accepted: 02/06/2002] [Indexed: 11/08/2022]
Abstract
It has been suggested that the expansion of the leukemic cells in chronic lymphocytic leukemia (CLL) is due to dysregulation of pathways of programmed cell death (apoptosis) rather than cell proliferation, although differences may exist in early vs late and treated vs untreated patients. In the present study, we analyzed the expression of 11 proteins in CLL cells that are implicated in the control of apoptosis, proliferation, and differentiation, and correlated this expression profile with survival. Using a quantitative solid-phase radioimmunoassay (RIA), we measured the cellular protein levels of Bcl-2, cyclin D1, PCNA, ATM, Fas, Bax, retinoic acid receptor alpha (RARalpha), retinoic acid receptor beta (RXRbeta), Flt1, VEGF, and cellular beta2-microglobulin in 230 samples of CLL. Univariate analysis using the Cox proportional hazard model showed a correlation with survival of only the following proteins: Bcl-2 (P < 0.001), cyclin D1 (P = 0.027), Fas (P = 0.055), PCNA (P < 0.001), and ATM (P = 0.028). In a multivariate analysis using classification and regression tree analysis (CART), five groups of patients (nodes) could be generated with significant differences of survival expectation (P < 0.0001) based on levels of expression of the above proteins. Based on CART analysis, Bcl-2 levels emerge as the most important protein in predicting survival between all 11 proteins studied. Patients with marked elevation in Bcl-2 levels had the worst outcome while patients with intermediate levels, but with high levels of PCNA and cyclin D1 or abnormal ATM expression had intermediate survival. These data indicate that intracellular levels of proteins such as Bcl-2, ATM, cyclin D1, and PCNA can be used as markers to predict clinical behavior and survival in patients with CLL. The pathways in which these proteins are involved may also represent possible targets for future therapeutic trials in CLL.
Collapse
MESH Headings
- Adult
- Aged
- Biomarkers, Tumor/metabolism
- Blotting, Western
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Male
- Middle Aged
- Neoplasm Proteins/metabolism
- Prognosis
- Proliferating Cell Nuclear Antigen/metabolism
- Proportional Hazards Models
- Proto-Oncogene Proteins c-bcl-2/metabolism
- Survival Analysis
Collapse
Affiliation(s)
- S Faderl
- Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
Increased angiogenesis is important in the pathophysiology of solid tumors. Recent studies show that angiogenesis and angiogenic factors play an important role in hematological malignancies. Both acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are associated with a substantial increase in vascularity in the bone marrow as well as increased levels of various angiogenic factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, angiogenin, angiopoietin-1, platelet-derived growth factor, hepatocyte growth factor, epidermal growth factor, tumor necrosis factor-alpha, and transforming growth factor-alpha and transforming growth factor-beta. Most of these angiogenic factors appear to be secreted by the neoplastic hematopoietic cells and appear to promote the growth and proliferation of the leukemic cells in an autocrine fashion. More importantly, angiogenic factors play a role in the clinical behavior and outcome of both AML and MDS. Despite significant overlap between MDS and AML in many aspects, higher levels of cellular VEGF and lower levels KDR are seen in MDS than in AML. Antiangiogenic therapy may play a role in AML and MDS and some differences in response may exist between MDS and AML.
Collapse
Affiliation(s)
- M Albitar
- Department of Leukemia and Hematopathology, University of Texas, M.D. Anderson Cancer Center, Houston, Tex 77030-4095, USA.
| |
Collapse
|
39
|
Abstract
Angiogenesis is a fundamental element of the physiological processes of embryogenesis and wound healing. During malignant transformation, dysregulation of angiogenesis leads to the formation of a vascular network of tumor-associated capillaries promoting survival and proliferation of the cancerous cells. Activation, migration, proliferation and differentiation of endothelial cells into mature blood vessels is driven by several cytokines and growth factors, known to be dysregulated in hematological malignancies. Thus, therapeutic interventions designed to eradicate the malignant clone should incorporate modulation of the angiogenic cascade. Antiangiogenic agents which target different components of the neovascularization process are being investigated in various solid tumors known to have increased vascularity. The role of angiogenesis in hematological malignancies, the rationale for the use of angiosuppressive therapy for these entities, and the status of novel antiangiogenic agents in clinical trials are discussed.
Collapse
Affiliation(s)
- D A Thomas
- Department of Leukemia, M.D. Anderson Cancer Center, Houston, Tex 77030, USA.
| | | | | | | | | |
Collapse
|
40
|
Oudat R, Keating MJ, Lerner S, O'Brien S, Albitar M. Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission. Leukemia 2002; 16:632-5. [PMID: 11960343 DOI: 10.1038/sj.leu.2402439] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2001] [Accepted: 12/20/2001] [Indexed: 11/09/2022]
Abstract
Patients with chronic lymphocytic leukemia (CLL) are considered in nodular partial remission (nPR) when they are in remission but bone marrow biopsies show rare nodules. The significance of the level of residual disease in nPR is not known. We studied 91 previously untreated CLL patients who were treated with fludarabine alone, fludarabine with prednisone, or fludarabine with cyclophosphamide and achieved nPR at the end of six courses. We compared bone marrow lymphoid infiltration before therapy and at the end of three and six courses of therapy as evaluated by a pathologist in retrospective fashion with that of the routine evaluation at the time of performing bone marrow biopsy. We then compared these results with those obtained by computer-aided histomorphometry in 28 patients in nPR. There was significant correlation (P < 0.05) between pathologists as well as between pathologists and histomorphometry. Upon correlation with clinical characteristics, there was significant correlation (P 0.01) between marrow involvement before therapy and white blood cell counts (wbc), hemoglobin (hgb), absolute lymphocyte counts, and beta2-microglobulin (beta2-m) but none of these parameters correlated with the lymphoid infiltrate at the end of three or six courses of therapy. more importantly, lymphoid infiltration after three and six courses did not correlate with time to progression (ttp) or overall survival (os). however, patients with >70% marrow involvement before therapy had a significantly shorter TTP (P = 0.02). All 91 patients showed similar results. However, we found reverse correlation between marrow lymphoid infiltrate at the end of three courses and OS (P = 0.01).
Collapse
MESH Headings
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biopsy, Needle
- Bone Marrow/pathology
- Bone Marrow Examination
- Disease Progression
- Female
- Follow-Up Studies
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Leukemic Infiltration/pathology
- Lymphoma, Follicular/mortality
- Lymphoma, Follicular/pathology
- Lymphoma, Follicular/therapy
- Male
- Middle Aged
- Prognosis
- Remission Induction
- Survival Rate
Collapse
Affiliation(s)
- R Oudat
- Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | |
Collapse
|
41
|
Albitar M, Manshouri T, Gidel C, Croce C, Kornblau S, Pierce S, Kantarjian HM. Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia. Leuk Res 2001; 25:859-64. [PMID: 11532518 DOI: 10.1016/s0145-2126(01)00042-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
The FHIT (fragile histidine triad) gene, which is located on 3p14.2 and believed to be a tumor suppressor gene, has been reported to lose its expression in several solid tumors and hematologic malignancies, including acute lymphoblastic leukemia (ALL). The clinical relevance of the loss of FHIT expression in ALL is not known. We used western blot and solid-phase radioimmunoassay (RIA) to analyze Fhit protein expression in 90 patients with ALL. Eighteen (20%) of the tested patients had severely reduced Fhit protein (undetectable by western blot), and 43 patients (47%) had levels lower than those detected in normal bone marrows. Interestingly, seven patients (8%) expressed very high levels (>two-fold the level detected in normal bone marrow). A parallel pattern of FHIT RNA expression was also observed. Of the 90 patients, 39 received induction therapy consisting of hyper-CVAD (hyperfractionated cyclophosphamide, vencristine, adriamycine, and dexamethasone) and were followed in our institution. Patients with low Fhit protein levels showed no statistically significant difference in survival or complete remission duration (CRD) from patients with normal levels (P=0.12 and 0.24, respectively). Our study confirms that FHIT is aberrantly expressed in ALL, but suggests it does not have a role as a prognostic factor. Studies with large numbers of patients and evaluation of the mechanisms of FHIT function in ALL are needed.
Collapse
Affiliation(s)
- M Albitar
- Department of Hematopathology, Box 72, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4095, USA.
| | | | | | | | | | | | | |
Collapse
|
42
|
Aboul-Nasr R, O'Brien S, Freireich EJ, Ginsberg CF, Kantarjian HM, Koller CA, Keating MJ, Albitar M. "T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow. Leuk Lymphoma 2001; 42:1023-31. [PMID: 11697619 DOI: 10.3109/10428190109097722] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We report four cases of a "T-cell-rich B-cell chronic lymphoproliferative disorder" involving the bone marrow and not extramedullary sites. The neoplastic B-cell proliferation in these cases was composed predominantly of small lymphoid cells with features of both hairy cell leukemia and lymphoplasmacytoid lymphoma. All cases presented with neutropenia and with difficulty in diagnosis. We present the clinical, morphologic, cytochemical, and immunophenotypic findings in these cases and discuss this entity.
Collapse
MESH Headings
- Adult
- Aged
- Bone Marrow/pathology
- Diagnosis, Differential
- Female
- Humans
- Leukemia, Hairy Cell/diagnosis
- Leukemia, Hairy Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Lymphoma, B-Cell/diagnosis
- Lymphoma, B-Cell/pathology
- Middle Aged
- Neutropenia/etiology
- T-Lymphocytes/cytology
Collapse
Affiliation(s)
- R Aboul-Nasr
- Division of Laboratory Medicine, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001; 116:437-43. [PMID: 11554173 DOI: 10.1309/438n-e0fh-a5pr-xcac] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
Differential expression of CD20 surface antigen in B-cell neoplasms at different sites is largely unknown. The number of CD20 antibodies bound per cell (CD20 ABC) in bone marrow (BM), peripheral blood (PB), and lymph node aspirate (LNA) samples from patients with B-cell chronic lymphocytic leukemia (B-CLL) or other B-cell disease was studied using quantitative flow cytometry. CD20 ABC differed significantly with the specimen type in B-CLL, being highest in PB (mean, 9,051) and lower in BM (mean, 4,067) and LNA (mean, 3,951). No difference in CD20 ABC between BM and PB samples was found in splenic lymphoma, mantle cell lymphoma, or follicular lymphoma. Also, we found a significant difference of CD20 ABC by type of disease: lowest in B-CLL; higher in splenic, follicular, and mantle cell lymphoma; and highest in hairy cell leukemia. The lower CD20 surface antigen levels in BM and LNA than in PB in B-CLL may have clinical relevance with regard to the efficacy of rituximab therapy.
Collapse
MESH Headings
- Adult
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20/analysis
- Antineoplastic Agents/therapeutic use
- B-Lymphocytes/immunology
- B-Lymphocytes/pathology
- Bone Marrow/immunology
- Bone Marrow/pathology
- Flow Cytometry
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Lymph Nodes/immunology
- Lymph Nodes/pathology
- Lymphoma, Follicular/immunology
- Lymphoma, Follicular/pathology
- Lymphoma, Mantle-Cell/immunology
- Lymphoma, Mantle-Cell/pathology
- Rituximab
- Splenic Neoplasms/immunology
- Splenic Neoplasms/pathology
Collapse
Affiliation(s)
- Y O Huh
- Departments of Hematopathology and Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009, USA
| | | | | | | | | | | |
Collapse
|
44
|
Verstovsek S, Kantarjian H, Aguayo A, Manshouri T, Freireich E, Keating M, Estey E, Albitar M. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 2001; 114:290-5. [PMID: 11529846 DOI: 10.1046/j.1365-2141.2001.02921.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Human angiogenin is a potent inducer of angiogenesis. The association between angiogenin and cancer progression and poor outcome in solid tumours has been documented, but its significance in leukaemias has not been evaluated. We evaluated plasma angiogenin levels in 101 previously untreated patients with acute myeloid leukaemia (AML) (59 patients) and advanced myelodysplastic syndrome (MDS) (42 patients). Angiogenin levels were significantly higher in AML and advanced MDS patients than in healthy individuals (P < 0.00001). Angiogenin levels were also significantly higher in advanced MDS than in AML (P = 0.001). Higher levels of angiogenin correlated with prolonged survival periods in both AML and advanced MDS patients (P = 0.02 and 0.01 respectively). We found no correlation between angiogenin plasma level and various patient characteristics, including age, performance status, antecedent haematological disorder, haemoglobin, white blood cell and platelet counts, and poor prognosis cytogenetics. There was no significant correlation between angiogenin level and complete remission rate and duration in AML or advanced MDS patients. In multivariate analysis, angiogenin concentration retained its significance as a prognostic factor in AML (P = 0.03), together with age (P = 0.00007) and haemoglobin (P = 0.03).
Collapse
Affiliation(s)
- S Verstovsek
- Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, Koller C, Estrov Z, Freireich E, Keating M, Albitar M. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 2001; 15:1165-70. [PMID: 11480557 DOI: 10.1038/sj.leu.2402182] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Hepatocyte growth factor (HGF) is a potent angiogenic factor. The aim of our study was to evaluate plasma HGF levels and their prognostic significance in patients with newly diagnosed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The sandwich enzyme immunoassay technique was used to quantify HGF in stored samples obtained before treatment from patients with AML (59 patients) and MDS (42 patients) treated at The University of Texas MD Anderson Cancer Center. HGF levels were significantly higher in patients with AML or MDS than in healthy individuals (P < 0.0001). Higher HGF levels in both AML and MDS correlated significantly with white blood cell (P = 0.000001 for both groups) and monocyte counts (P = 0.0004 and 0.003, respectively), and with poor performance status (P = 0.03 and 0.001, respectively). Using Cox proportional hazard model and HGF levels as a continuous variable, plasma levels of HGF correlated with shorter survival of AML (P = 0.001), but not MDS (P = 0.34) patients. No significant correlation was observed between HGF levels and complete remission rate or duration. In the multivariate analysis HGF retained its significance as prognostic factor in AML (P = 0.02), along with age (P = 0.0005).
Collapse
Affiliation(s)
- S Verstovsek
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Verstovsek S, Estey E, Manshouri T, Keating M, Kantarjian H, Giles FJ, Albitar M. High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma 2001; 42:511-6. [PMID: 11699417 DOI: 10.3109/10428190109064609] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The tyrosine kinase receptor Tie-1 has been shown to play a role in angiogenesis and hematopoiesis. We evaluated the level of expression and clinical significance of Tie-1 protein in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We used western blot analysis to confirm and radioimmunoassay to quantify Tie-1 protein expression in bone marrow samples obtained from untreated patients having AML (66 patients) or MDS (29 patients). Samples obtained from these patients contained significantly higher levels of Tie-1 protein than did control samples (P < 0.001). Also, Tie-1 levels were significantly higher in AML patients than MDS patients (P < 0.0001). Tie-1 levels did not correlate with complete remission or survival duration in patients having either disease. These data suggest that Tie-1 expression is increased in AML and MDS but that the level of expression does not influence the response to current therapy. The role of Tie-1 overexpression in the reported increased vascularity in the bone marrow of AML and MDS patients requires further investigation.
Collapse
Affiliation(s)
- S Verstovsek
- Department of Leukemia, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
| | | | | | | | | | | | | |
Collapse
|
47
|
Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM, Albitar M. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98:181-6. [PMID: 11418478 DOI: 10.1182/blood.v98.1.181] [Citation(s) in RCA: 292] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CD38 is a transmembrane glycoprotein expressed on the surface of leukemic cells in a significant percentage of patients with B-cell chronic lymphocytic leukemia (B-CLL). A recent study suggested that CD38 expression has prognostic value in CLL. Peripheral blood samples from 218 patients with B-CLL were analyzed by flow cytometry for CD38 expression on CD5/19(+) leukemic cells. Various patient characteristics were studied including age, sex, Rai and Binet stages, splenomegaly, hepatomegaly, hemoglobin (Hgb) level, beta-2 microglobulin (beta2M) level in the serum, number of nodal sites involved with disease, and length of survival. The Kaplan-Meier method was used to construct survival curves, and the log-rank statistic was used to compare these curves. CD38 was expressed in 20% or more of leukemic cells in 43% of the patients. Patients with high CD38 expression (20% or more) had significantly shorter survival times (P =.00005). Multivariate analyses showed that CD38 expression is an important prognostic factor associated with high incidence of lymph node involvement (P =.004), lower hemoglobin level (P =.001), hepatomegaly (P =.05), and high beta2M level (P =.00005). CD38 expression identified a group of patients with aggressive disease that was considered by Rai staging to be early-stage disease (Rai stages 0-II). Patients with CD38(+) samples have significantly aggressive disease regardless of their clinical stage. Measurement of CD38 expression by flow cytometry should become a routine test in the evaluation of patients with CLL.
Collapse
Affiliation(s)
- S Ibrahim
- Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, Schlette ES, Faderl S, Sarris A, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma 2001; 42:329-37. [PMID: 11699397 DOI: 10.3109/10428190109064589] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Approximately 3 to 5% of patients with chronic lymphocytic leukemia (CLL) develop an aggressive large cell non Hodgkin's lymphoma (NHL) known as Richter's syndrome (RS). RS has a poor prognosis and a response rate of < 10% with fludarabine-based or other cytotoxic combination regimens. The aim of this study was to evaluate the efficacy and toxicity of the hyperCVXD regimen in RS. Twenty-nine patients, median age 61 years (36-75) 23 males, were treated. Prior diagnosis was CLL in 26 patients, NHL in 2, and Prolymphocytic leukemia in 1. Treatment consisted of fractionated cyclophosphamide, vincristine, daunoXome and dexamethasone. Six patients (20%) died while receiving study therapy, 4 (14%) during the first cycle of whom 2 had started therapy with overt pneumonia. Grade 4 granulocytopenia occurred in all 95 cycles of therapy with a median time to recovery of 14 days. Twenty three (24%) cycles were complicated by fever, and 15 (15%) by pneumonia. Sepsis was documented in 8 (8%) cycles, and neuropathy in 5 (5%) of cycles. Twenty three patients had a platelet count < 100 x 10(9)/l prior to therapy: a greater than 50% decrease in platelet count over pre-therapy level occurred in 79% of first cycles, overt bleeding occurred in 4 (4%) of all cycles. Eleven of 29 (38%) patients achieved complete remission (CR), 4 of whom have relapsed after 5, 6, 9, and 12 months of remission. Two of 11 CR patients presented with RS without any prior CLL therapy. One patient had a partial remission. Thus the overall response rate was 12/29 (41%). Overall median survival was 10 months, 19 months in patients who achieved CR, 3 months in those who did not (p = 0.0008). A landmark analysis performed at 2 months from start of therapy comparing patients alive in CR versus patients alive but not in CR showed a median survival of 19 months versus 6 months, respectively (p 0.0017). In conclusion the hyper CVXD regimen has a relatively high response rate, significant toxicity and a moderate impact on survival in RS.
Collapse
MESH Headings
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Cyclophosphamide/administration & dosage
- Dexamethasone/administration & dosage
- Drug Carriers
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Liposomes
- Lymphoma, Large B-Cell, Diffuse/complications
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Male
- Middle Aged
- Survival Rate
- Syndrome
- Time Factors
- Vincristine/administration & dosage
Collapse
Affiliation(s)
- B S Dabaja
- Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar M. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer 2001; 91:1964-72. [PMID: 11391574 DOI: 10.1002/1097-0142(20010601)91:11<1964::aid-cncr1221>3.0.co;2-b] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND The mechanisms favoring the growth advantage of Philadelphia chromosome positive cells over normal cells in chronic myelogenous leukemia (CML) are not fully elucidated but could be due partly to altered apoptosis and longer survival of CML clones. Also, little is known about the biologic characteristics of disease progression in CML. Bcl-2 expression has been demonstrated to exert an antiapoptotic effect resulting in increased cell survival. Other proteins such as Bax and Bad are proapoptotic proteins. Fas, a cell surface protein, can be triggered by an appropriate death-promoting ligand (FasL) to activate downstream caspases pivotal in initiation of programmed cell death. Although the mechanisms underlying cellular proliferative and apoptotic pathways are complex, with involvement of multiple interlocking proteins, the relative expression of pro- and antiapoptotic proteins may have an influence on disease progression. This study aimed to determine whether the changes in the cellular expression of Bcl-2, Bax, and Fas correlate with caspase-3 activity and disease progression in CML, or with response to interferon (IFN)-alpha therapy and prognosis in early chronic phase CML. METHODS Bcl-2, Bax, and Fas expression were measured on whole cell lysates from bone marrow mononuclear cell fractions by Western blot analysis and quantitative radioimmunoassay. Caspase-3 activity was determined using the DEVD system. Specimens from 203 patients with CML were examined. These included 130 patients in early chronic phase disease (ECP; diagnosis to therapy, < or =12 months), 33 patients in late chronic phase (diagnosis to therapy, > 12 months), 27 patients in accelerated phase, and 13 patients in blastic phase. Correlations between apoptosis proteins and CML phases, risk groups in ECP, and response to IFN-alpha therapy and survival in ECP were investigated by standard statistical methods, and positive findings were assessed by multivariate analysis. RESULTS Levels of Bcl-2, Fas, Bax, and caspase-3 activity did not correlate with disease progression. Among patients in ECP, higher Fas levels correlated with poorer risk groups (P = 0.05) and higher caspase-3 activity correlated with better risk groups (P = 0.048). With IFN-alpha therapy, major cytogenetic responses were noted in 30% of patients with high Fas and 53% with low Fas (P = 0.016) and failure to achieve a complete hematologic response (CHR) in 25% versus 2% (P = 0.0001). Survival was shorter with high Fas levels (5-year rates, 71% vs. 52%; P = 0.002), and the independent poor prognostic significance of high Fas levels was confirmed by multivariate analysis (P = 0.014). Response to IFN-alpha therapy and survival were not significantly different by different levels of Bcl-2, Bax, or caspase-3 activity. CONCLUSIONS High Fas levels were associated with intrinsically worse disease at diagnosis, whereas high caspase-3 activity was associated with good risk disease. In ECP CML, high Fas levels were associated with significantly worse response to IFN-alpha therapy and with significantly worse survival. The influence of these cellular proteins and caspase-3 activity on apoptosis in CML is complex and merits further investigation.
Collapse
Affiliation(s)
- F Ravandi
- Department of Leukemia, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Verstovsek S, Manshouri T, Kantarjian H, Giles FJ, Keating M, Estey E, Albitar M. Highly Reproducible Detection and Semi-Quantification of Telomerase Activity. Biotechniques 2001; 30:930-4. [PMID: 11355351 DOI: 10.2144/01305bm01] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- S Verstovsek
- University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | | | | | | | | | | | | |
Collapse
|